Table 1.

Clinical characteristics of TMA, NanoString, and TCGA Firehose Legacy patient groups.

	All Patients	Women	Men	p-value
Number
IHC	101	51	50	0.953
NanoString	32	17	15	0.501
Firehose	633	297	336	0.05
Age (years)
IHC	60.9 ± 13.0	60.7 ± 14.0	61.1 ± 12.0	0.865
NanoString	58.7 ± 12.6	58.7 ± 12.6	58.8 ± 12.8	0.991
Firehose	66.0 ± 12.8	66.0 ± 13.8	66.0 ± 11.9	0.992
Stage
IHC				0.513
I	23	12	11
II	24	12	12
III	43	21	22
IV	11	6	5
NanoString				0.253
I	5	4	1
II	11	3	8
III	4	3	1
IV	10	6	4
Unknown	2	1	1
Firehose	109	48	61	0.104
I	230	109	121
II	182	92	90
III	91	40	51
IV	21	8	13
MSI
IHC	5	3	2	0.902
NanoString	12.4 ± 9.5	10.6 ± 7.2	13.7 ± 10.9	0.504
Survival (months)
IHC	41.0 ± 26.2	38.0 ± 23.8	45.0 ± 28.7	0.902
NanoString	12.4 ± 9.5	10.6 ± 7.2	13.7 ± 10.9	0.504

P-values represent comparison between women and men.